WINTON GROUP Ltd Invests $16.33 Million in PAREXEL International Corporation (PRXL)

WINTON GROUP Ltd bought a new stake in PAREXEL International Corporation (NASDAQ:PRXL) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 187,884 shares of the medical research company’s stock, valued at approximately $16,329,000. WINTON GROUP Ltd owned about 0.37% of PAREXEL International Corporation as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. lifted its holdings in shares of PAREXEL International Corporation by 22,876.6% in the 1st quarter. BlackRock Inc. now owns 5,513,456 shares of the medical research company’s stock valued at $347,955,000 after purchasing an additional 5,489,460 shares during the last quarter. Vanguard Group Inc. increased its position in PAREXEL International Corporation by 0.9% in the 2nd quarter. Vanguard Group Inc. now owns 4,205,566 shares of the medical research company’s stock valued at $365,506,000 after acquiring an additional 39,302 shares during the period. Credit Suisse AG increased its position in PAREXEL International Corporation by 1,897.2% in the 1st quarter. Credit Suisse AG now owns 2,093,297 shares of the medical research company’s stock valued at $132,108,000 after acquiring an additional 1,988,488 shares during the period. State Street Corp increased its position in PAREXEL International Corporation by 4.3% in the 2nd quarter. State Street Corp now owns 1,744,373 shares of the medical research company’s stock valued at $151,607,000 after acquiring an additional 71,255 shares during the period. Finally, Alpine Associates Management Inc. acquired a new position in PAREXEL International Corporation in the 2nd quarter valued at about $113,716,000. 87.45% of the stock is owned by institutional investors and hedge funds.

PAREXEL International Corporation (PRXL) traded down 0.02% during trading on Friday, reaching $88.08. The company’s stock had a trading volume of 7,021,106 shares. The stock has a market capitalization of $4.50 billion, a price-to-earnings ratio of 42.76 and a beta of 0.77. The firm has a 50 day moving average of $87.85 and a 200 day moving average of $79.27. PAREXEL International Corporation has a 52 week low of $51.16 and a 52 week high of $88.10.

PAREXEL International Corporation (NASDAQ:PRXL) last released its quarterly earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.08. The company had revenue of $557.20 million for the quarter, compared to analysts’ expectations of $537.59 million. PAREXEL International Corporation had a return on equity of 28.98% and a net margin of 4.49%. During the same quarter in the previous year, the company posted $0.94 earnings per share. Analysts expect that PAREXEL International Corporation will post $4.06 EPS for the current year.

WARNING: This piece of content was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://ledgergazette.com/2017/10/14/winton-group-ltd-invests-16-33-million-in-parexel-international-corporation-prxl.html.

Several brokerages recently issued reports on PRXL. Zacks Investment Research upgraded PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 price target on the stock in a research report on Tuesday, August 8th. Barclays PLC cut PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price target on the stock. in a research report on Tuesday, June 20th. Jefferies Group LLC restated a “hold” rating and issued a $88.10 price target on shares of PAREXEL International Corporation in a research report on Wednesday, June 21st. Raymond James Financial, Inc. upgraded PAREXEL International Corporation from an “underperform” rating to a “mkt perform̶

Several other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. lifted its holdings in shares of PAREXEL International Corporation by 22,876.6% in the 1st quarter. BlackRock Inc. now owns 5,513,456 shares of the medical research company’s stock valued at $347,955,000 after purchasing an additional 5,489,460 shares during the last quarter. Vanguard Group Inc. increased its position in PAREXEL International Corporation by 0.9% in the 2nd quarter. Vanguard Group Inc. now owns 4,205,566 shares of the medical research company’s stock valued at $365,506,000 after acquiring an additional 39,302 shares during the period. Credit Suisse AG increased its position in PAREXEL International Corporation by 1,897.2% in the 1st quarter. Credit Suisse AG now owns 2,093,297 shares of the medical research company’s stock valued at $132,108,000 after acquiring an additional 1,988,488 shares during the period. State Street Corp increased its position in PAREXEL International Corporation by 4.3% in the 2nd quarter. State Street Corp now owns 1,744,373 shares of the medical research company’s stock valued at $151,607,000 after acquiring an additional 71,255 shares during the period. Finally, Alpine Associates Management Inc. acquired a new position in PAREXEL International Corporation in the 2nd quarter valued at about $113,716,000. 87.45% of the stock is owned by institutional investors and hedge funds.

PAREXEL International Corporation (PRXL) traded down 0.02% during trading on Friday, reaching $88.08. The company’s stock had a trading volume of 7,021,106 shares. The stock has a market capitalization of $4.50 billion, a price-to-earnings ratio of 42.76 and a beta of 0.77. The firm has a 50 day moving average of $87.85 and a 200 day moving average of $79.27. PAREXEL International Corporation has a 52 week low of $51.16 and a 52 week high of $88.10.

PAREXEL International Corporation (NASDAQ:PRXL) last released its quarterly earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.08. The company had revenue of $557.20 million for the quarter, compared to analysts’ expectations of $537.59 million. PAREXEL International Corporation had a return on equity of 28.98% and a net margin of 4.49%. During the same quarter in the previous year, the company posted $0.94 earnings per share. Analysts expect that PAREXEL International Corporation will post $4.06 EPS for the current year.

WARNING: This piece of content was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://ledgergazette.com/2017/10/14/winton-group-ltd-invests-16-33-million-in-parexel-international-corporation-prxl.html.

Several brokerages recently issued reports on PRXL. Zacks Investment Research upgraded PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 price target on the stock in a research report on Tuesday, August 8th. Barclays PLC cut PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price target on the stock. in a research report on Tuesday, June 20th. Jefferies Group LLC restated a “hold” rating and issued a $88.10 price target on shares of PAREXEL International Corporation in a research report on Wednesday, June 21st. Raymond James Financial, Inc. upgraded PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a research report on Tuesday, June 20th. Finally, BidaskClub cut PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $75.92.

PAREXEL International Corporation Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply